文献速递糖尿病

每周一次司美格鲁肽单药治疗与安慰剂对比在2型糖尿病患者中的疗效与安全性(SUSTAIN 1):一项双盲、随机、安慰剂对照、平行组、多国、多中心3a期试验

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-01-17

SUSTAIN 1研究在加拿大等8国72个中心纳入388例仅饮食运动治疗且血糖控制不佳的2型糖尿病患者,随机接受每周一次皮下注射司美格鲁肽0.5mg、1.0mg或安慰剂治疗30周;两剂量司美格鲁肽均显著降低HbA1c和体重,安全性与现有GLP-1受体激动剂相似,为潜在治疗选择。

要点

  • 司美格鲁肽0.5mg和1.0mg每周一次治疗30周,HbA1c较基线分别降低1.45%和1.55%,均显著优于安慰剂。
  • 两剂量司美格鲁肽体重较基线分别降低3.73kg和4.53kg,均显著优于安慰剂。
  • 最常见不良事件为胃肠道反应(恶心、腹泻),多数为轻中度,无死亡报告。

核心结论

  • 司美格鲁肽显著改善2型糖尿病患者的HbA1c和体重,安全性与现有GLP-1受体激动剂相似,是此类患者的潜在治疗选择。

研究设计与样本

  • 双盲、随机、平行组、国际、安慰剂对照3a期试验(SUSTAIN 1),在加拿大、意大利、日本、墨西哥、俄罗斯、南非、英国和美国的72个中心进行。
  • 纳入388例18岁及以上、仅饮食运动治疗至少30天、基线HbA1c 7.0%-10.0%(53-86 mmol/mol)的初治2型糖尿病患者,按2:2:1:1随机分配至每周一次皮下注射司美格鲁肽0.5mg、1.0mg或容积匹配安慰剂0.5mg、1.0mg,治疗30周。
  • 387例接受至少一剂研究药物(司美格鲁肽0.5mg组128例、1.0mg组130例、安慰剂组129例),疗效和安全性在改良意向治疗人群中评估,两个安慰剂组合并分析。

主要发现

  • 第30周时,司美格鲁肽0.5mg组HbA1c较基线显著降低1.45%(95%CI -1.65至-1.26),1.0mg组显著降低1.55%(-1.74至-1.36),安慰剂组非显著降低0.02%(-0.23至0.18);与安慰剂的估计治疗差异分别为-1.43%(95%CI -1.71至-1.15;p<0.0001)和-1.53%(-1.81至-1.25;p<0.0001)。
  • 第30周时,司美格鲁肽0.5mg组体重较基线显著降低3.73kg(95%CI -4.54至-2.91),1.0mg组显著降低4.53kg(-5.34至-3.72),安慰剂组非显著降低0.98kg(-1.82至-0.13);与安慰剂的估计治疗差异分别为-2.75kg(95%CI -3.92至-1.58;p<0.0001)和-3.56kg(-4.74至-2.38;p<0.0001)。
  • 恶心报告率:司美格鲁肽0.5mg组26例(20%)、1.0mg组31例(24%)、安慰剂组10例(8%);腹泻报告率:0.5mg组16例(13%)、1.0mg组14例(11%)、安慰剂组3例(2%)。
  • 未报告死亡,大多数不良事件为轻中度;因不良事件停药的主要原因为恶心等胃肠道事件,0.5mg组17例(13%)、1.0mg组16例(12%)、安慰剂组14例(11%)停止治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite a broad range of pharmacological options for the treatment of type 2 diabetes, optimum glycaemic control remains challenging for many patients and new therapies are necessary. Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 development for type 2 diabetes. We assessed the efficacy, safety, and tolerability of semaglutide monotherapy, compared with placebo, in treatment-naive patients with type 2 diabetes who had insufficient glycaemic control with diet and exercise alone. METHODS: We did a double-blind, randomised, parallel-group, international, placebo-controlled phase 3a trial (SUSTAIN 1) at 72 sites in Canada, Italy, Japan, Mexico, Russia, South Africa, UK, and USA (including hospitals, clinical research units, and private offices). Eligible participants were treatment-naive individuals aged 18 years or older with type 2 diabetes treated with only diet and exercise alone for at least 30 days before screening, with a baseline HbA1c of 7·0%-10·0% (53-86 mmol/mol). We randomly assigned participants (2:2:1:1) to either once-weekly subcutaneously injected semaglutide (0·5 mg or 1·0 mg), or volume-matched placebo (0·5 mg or 1·0 mg), for 30 weeks via prefilled PDS290 pen-injectors. Participants did their own injections and were encouraged to administer them on the same day of each week in the same area of their body; the time of day and proximity of meal times was not specified. We did the randomisation with an interactive voice or web response system. Investigators, participants, and the funder of the study remained masked throughout the trial. The primary endpoint was the change in mean HbA1c from baseline to week 30, and the confirmatory secondary endpoint was the change in mean bodyweight from baseline to week 30. We assessed efficacy and safety in the modified intention-to-treat population (ie, all participants who were exposed to at least one dose of study drug); both placebo groups were pooled for assessment. This trial was registered with ClinicalTrials.gov, number NCT02054897. FINDINGS: Between February 3, 2014, and August 21, 2014, we randomly assigned 388 participants to treatment; 387 received at least one dose of study medication (128 0·5 mg semaglutide, 130 1·0 mg semaglutide, 129 placebo). 17 (13%) of those assigned to 0·5 mg semaglutide, 16 (12%) assigned to 1·0 mg semaglutide, and 14 (11%) assigned to placebo discontinued treatment; the main reason for discontinuation was gastrointestinal adverse events such as nausea. Mean baseline HbA1c was 8·05% (SD 0·85); at week 30, HbA1c significantly decreased by 1·45% (95% CI -1·65 to -1·26) with 0·5 mg semaglutide (estimated treatment difference vs placebo -1·43%, 95% CI -1·71 to -1·15; p<0·0001), significantly decreased by 1·55% (-1·74 to -1·36) with 1·0 mg semaglutide (estimated treatment difference vs placebo -1·53%, -1·81 to -1·25; p<0·0001), and non-significantly decreased by 0·02% (-0·23 to 0·18) with placebo. Mean baseline bodyweight was 91·93 kg (SD 23·83); at week 30, bodyweight significantly decreased by 3·73 kg (95% CI -4·54 to -2·91) with 0·5 mg semaglutide (estimated treatment difference vs placebo -2·75 kg, 95% CI -3·92 to -1·58; p<0·0001), significantly decreased by 4·53 kg (-5·34 to -3·72) with 1·0 mg semaglutide (estimated treatment difference vs placebo -3·56 kg, -4·74 to -2·38; p<0·0001), and non-significantly decreased by 0·98 kg (-1·82 to -0·13) with placebo. No deaths were reported in any of the study groups and most reported adverse events were of mild or moderate severity. The most frequently reported adverse events in both semaglutide groups were gastrointestinal in nature: nausea was reported in 26 (20%) who received 0·5 mg semaglutide, 31 (24%) who received 1·0 mg semaglutide, and 10 (8%) who received placebo, and diarrhoea was reported in 16 (13%) who received 0·5 mg semaglutide, 14 (11%) who received 1·0 mg semaglutide, and three (2%) who received placebo. INTERPRETATION: Semaglutide significantly improved HbA1c and bodyweight in patients with type 2 diabetes compared with placebo, and showed a similar safety profile to currently available GLP-1 receptor agonists, representing a potential treatment option for such patients. FUNDING: Novo Nordisk A/S, Denmark.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017. PMID: 28110911. doi:10.1016/S2213-8587(17)30013-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。